Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IgA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    681 result(s) found for: IgA. Displaying page 8 of 35.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2014-005339-15 Sponsor Protocol Number: CAIN457A3302 Start Date*: 2015-05-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 ...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) IE (Completed) NL (Completed) CZ (Completed) SK (Completed) AT (Completed) BE (Completed) HU (Completed) SE (Completed) DE (Completed) BG (Completed) DK (Completed) FI (Completed) LV (Completed) LT (Completed) FR (Completed) GR (Completed) GB (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001888-75 Sponsor Protocol Number: RD.06.SPR.118169 Start Date*: 2020-07-28
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002344-73 Sponsor Protocol Number: LTS17367(KY1005-CT06) Start Date*: 2022-07-12
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis who participated ...
    Medical condition: Dermatitis atopic
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003384-38 Sponsor Protocol Number: R668-AD-1415 Start Date*: 2015-02-18
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONS...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) DE (Completed) FI (Completed) SE (Completed) GB (Completed) DK (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002619-40 Sponsor Protocol Number: R668-AD-1416 Start Date*: 2015-03-25
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) IT (Completed) GB (Completed) SE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004574-34 Sponsor Protocol Number: I4V-MC-JAIN Start Date*: 2018-04-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moder...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) AT (Completed) BE (Completed) PL (Completed) FI (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001036-23 Sponsor Protocol Number: CASM981C2442 Start Date*: 2004-11-05
    Sponsor Name:Novartis Sverige AB
    Full Title: A 12-week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of El...
    Medical condition: atopic dermatitis (atopic eczema)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000985-39 Sponsor Protocol Number: CAIN457A2304E1 Start Date*: 2012-09-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, double-blind and open label, 4 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) SK (Completed) DE (Completed) AT (Completed) IT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004765-90 Sponsor Protocol Number: DFD03-CD-004 Start Date*: 2016-07-13
    Sponsor Name:Dr. Reddy’s Laboratories, Ltd
    Full Title: A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
    Medical condition: Acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005258-20 Sponsor Protocol Number: CAIN457ADE06 Start Date*: 2015-03-13
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 24-week, randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm® in adults with moderate to severe plaque p...
    Medical condition: chronic moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023127-23 Sponsor Protocol Number: ALV003-1021 Start Date*: 2010-10-25
    Sponsor Name:Alvine Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Double-Blind, Placebo Controlled Trial of the Efficacy, Safety and Tolerability of 6-Weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celia...
    Medical condition: Celiac Disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007864 Celiac disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000467-16 Sponsor Protocol Number: SP14019-18 Start Date*: 2016-06-16
    Sponsor Name:Spherium Biomed
    Full Title: EVALUATION OF SP14019-F-01 TOPICAL SOLUTION FOR THE TREATMENT OF ATOPIC DERMATITIS. PILOT STUDY (CYCLATOP STUDY)
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005513-72 Sponsor Protocol Number: B7451006 Start Date*: 2016-07-21
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE AT...
    Medical condition: ATOPIC DERMATITIS
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012221-10 Sponsor Protocol Number: ALV003-0921 Start Date*: 2009-07-21
    Sponsor Name:Alvine Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Double Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-week Treatment With ALV003 In Patients With Well-Controlled Celiac Disease
    Medical condition: Celiac Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007864 Celiac disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002060-26 Sponsor Protocol Number: 1401201 Start Date*: 2006-12-04
    Sponsor Name:Intendis GmbH
    Full Title: A double-blind, randomized, vehicle-controlled, 6-week exploratory multicenter pilot study of the efficacy and safety of Azelaic Acid (AzA) 15% gel in the topical treatment of mild to moderate seb...
    Medical condition: Patients with mild to moderate seborrheic dermatitis of the facial area and meeting the specific eligibility criteria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012488 Dermatitis seborrheic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002612-14 Sponsor Protocol Number: TMP-0517 Start Date*: 2019-06-25
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
    Full Title: Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata: A phase II, single centre, open label, proof of concept study for the treatment of acne conglobata with the PDE-4 ...
    Medical condition: Mild to severe Acne conglobata in adults (ages 18 to 65 years, inclusive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000501 Acne conglobata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005382-40 Sponsor Protocol Number: DFD-29-CD-005 Start Date*: 2022-06-15
    Sponsor Name:Dr. Reddy's Laboratories Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatm...
    Medical condition: Rosacea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002962-15 Sponsor Protocol Number: LP0133-1403 Start Date*: 2021-08-10
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 extension trial of DELTA 1 and DELTA 2 to evaluate the long-term safety of a twice-daily treatment with delgocitinib cream 20 mg/g as needed for up to 36 weeks in adult subjects with chro...
    Medical condition: Chronic Hand Eczema
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004858 10084778 Chronic hand eczema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Completed) FR (Completed) ES (Ongoing) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001136-21 Sponsor Protocol Number: B7451013 Start Date*: 2018-10-22
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with M...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) CZ (Completed) GB (Completed) DE (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-003899-12 Sponsor Protocol Number: 271-12-205 Start Date*: 2014-10-22
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Protocol 271-12-205: A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Oint...
    Medical condition: Mild/Moderate Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    17.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    17.1 10040785 - Skin and subcutaneous tissue disorders 10014982 Epidermal and dermal conditions HLGT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:10:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA